한글목차

세계의 외상성 뇌손상 치료학 시장은 2030년까지 137억 달러에 달할 전망

2023년에 59억 달러로 추정되는 세계의 외상성 뇌손상 치료학 시장은 2023-2030년 분석 기간 중에 12.7%의 CAGR로 성장하며, 2030년에는 137억 달러에 달할 것으로 예측됩니다. 아세틸콜린에스테라아제 저해제는 본 리포트에서 분석한 부문의 하나이며, CAGR 12.5%를 기록하며, 분석 기간 종료시에는 38억 달러에 달할 것으로 예측됩니다. 에리스로포이에틴 제제 부문의 성장률은 분석 기간 중 CAGR 11.5%로 추정됩니다.

미국 시장은 16억 달러, 중국은 CAGR 11.8%로 성장할 것으로 예측

미국의 외상성 뇌손상 치료학 시장은 2023년에 16억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 21억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년의 CAGR은 11.8%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 11.6%와 10.8%로 예측됩니다. 유럽에서는 독일이 CAGR 약 9.3%로 성장할 것으로 예측됩니다.

세계의 외상성 뇌손상 치료학 시장 - 주요 동향과 촉진요인 정리

외상성 뇌손상(TBI)은 매년 전 세계에서 수백만 명이 영향을 받는 심각한 공중보건 문제로, 낙상, 자동차 사고, 스포츠 외상, 폭행 등 외부의 힘에 의해 뇌가 손상되는 경우 발생하며, TBI의 심각성은 경미한 뇌진탕부터 심각한 뇌손상까지 다양합니다. 장기적인 장애와 사망에 이르기까지 다양합니다. 현재 TBI의 치료 전략에는 두개내압을 낮추고 추가 손상을 예방하기 위한 수술과 같은 급성기 개입과 인지적, 신체적, 정서적 장애를 치료하기 위한 장기적인 재활치료가 포함됩니다. 약리학적 치료는 증상을 관리하고 염증, 산화 스트레스, 흥분성 독성으로 인한 이차적 뇌 손상을 예방하는 것을 목표로 합니다. 다양한 치료법이 있음에도 불구하고, TBI의 경과를 크게 변화시킬 수 있는 효과적인 치료법은 제한적이어서 혁신적인 치료법의 필요성이 강조되고 있습니다.

최근 TBI의 병태생리에 대한 이해가 진전되면서 새로운 치료 전략의 길이 열리고 있습니다. 항산화제, 항염증약, 칼슘 채널 차단제와 같은 신경 보호제에 대한 연구는 초기 손상 후 2차 손상을 줄일 수 있는 가능성을 보여주고 있습니다. 줄기세포 치료는 조직 재생과 기능 회복의 가능성을 제공하는 새로운 분야이기도 합니다. 또한 바이오마커 탐색의 발전으로 TBI를 정확하게 진단하고 치료 효과를 모니터링할 수 있는 능력이 향상되어 보다 개인화된 치료 계획의 길을 열어가고 있습니다. 고압산소치료나 경두개 자기자극과 같은 비약리학적 중재도 신경가소성 및 회복을 촉진할 수 있는 가능성도 검토되고 있습니다. 이러한 혁신적인 접근법은 TBI의 근본적인 복잡한 메커니즘을 더 깊이 이해함으로써 환자에게 보다 효과적이고 종합적인 치료를 제공하기 위해 추진되고 있습니다.

TBI 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 스포츠 활동, 군적 충돌, 교통사고 등으로 인한 TBI 발생률 증가로 효과적인 치료에 대한 수요가 증가하고 있습니다. 첨단 영상 진단 기술 및 바이오마커 분석과 같은 진단 툴의 기술 발전으로 TBI의 진단 정확도 및 치료 경과 모니터링이 향상되고 있습니다. 재생의학, 특히 줄기세포 연구 분야의 확대는 이전에는 불가능했던 치료적 개입을 위한 새로운 길을 제공합니다. 또한 TBI가 삶의 질에 장기적인 영향을 미칩니다는 인식이 확산되면서 새로운 치료법 연구개발에 대한 투자가 증가하고 있으며, TBI 환자의 예후를 개선하기 위한 정부의 구상과 자금 지원, 학술기관과 제약사 간의 협력도 이 분야의 기술 혁신을 촉진하고 있습니다. 또한 맞춤형 의료의 부상으로 각 환자의 고유한 요구에 맞는 맞춤형 치료 접근법 개발이 촉진되어 TBI 치료의 전반적인 효과를 높이고 있습니다. 이러한 요인들로 인해 외상성 뇌손상 치료 시장은 역동적이고 빠르게 발전하고 있습니다.

조사 대상 기업의 예(총 86건)

• Abliva
• Algernon Pharmaceuticals Inc.
• Altasciences
• Astrocyte Pharmaceuticals Inc.
• Beyond Barriers Therapeutics, Inc.
• Cellvation, Inc.
• Ischemix
• Mitochon Pharmaceuticals
• NervGen Pharma Corp.
• Neuren Pharmaceuticals Ltd.
• SanBio Company Limited
• Symbinas Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• ZyVersa Therapeutics, Inc.

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Traumatic Brain Injury Therapeutics Market to Reach US$13.7 Billion by 2030

The global market for Traumatic Brain Injury Therapeutics estimated at US$5.9 Billion in the year 2023, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2023-2030. Acetylcholinesterase Inhibitors, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Erythropoietin Drugs segment is estimated at 11.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 11.8% CAGR

The Traumatic Brain Injury Therapeutics market in the U.S. is estimated at US$1.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 11.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.6% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global Traumatic Brain Injury Therapeutics Market - Key Trends and Drivers Summarized

Traumatic brain injury (TBI) is a significant public health concern, affecting millions of people worldwide each year. TBI occurs when an external force injures the brain, which can result from falls, motor vehicle accidents, sports injuries, or assaults. The severity of TBI ranges from mild concussions to severe brain damage, leading to long-term disabilities or even death. Current therapeutic strategies for TBI include acute interventions, such as surgery to reduce intracranial pressure and prevent further injury, as well as long-term rehabilitation efforts to address cognitive, physical, and emotional impairments. Pharmacological treatments are aimed at managing symptoms and preventing secondary brain damage caused by inflammation, oxidative stress, and excitotoxicity. Despite the array of interventions, effective treatments that can significantly alter the course of TBI remain limited, highlighting a critical need for innovative therapeutic approaches.

Recent advancements in the understanding of TBI pathophysiology have paved the way for novel therapeutic strategies. Research into neuroprotective agents, such as antioxidants, anti-inflammatory drugs, and calcium channel blockers, shows promise in mitigating the secondary damage following the initial injury. Stem cell therapy is another emerging field, offering potential for tissue regeneration and functional recovery. Additionally, advancements in biomarker discovery are enhancing the ability to diagnose TBI accurately and monitor treatment efficacy, paving the way for more personalized treatment plans. Non-pharmacological interventions, including hyperbaric oxygen therapy and transcranial magnetic stimulation, are also being explored for their potential to enhance neuroplasticity and recovery. These innovative approaches are driven by a deeper understanding of the complex mechanisms underlying TBI, aiming to provide more effective and comprehensive care for patients.

The growth in the TBI therapeutics market is driven by several factors. The increasing incidence of TBI due to sports activities, military conflicts, and road accidents has heightened the demand for effective treatments. Technological advancements in diagnostic tools, such as advanced imaging techniques and biomarker assays, have improved the accuracy of TBI diagnosis and the monitoring of treatment progress. The expanding field of regenerative medicine, particularly stem cell research, offers new avenues for therapeutic interventions that were previously unattainable. Moreover, the growing awareness of the long-term impact of TBI on quality of life is propelling investment in research and development of new treatments. Government initiatives and funding aimed at improving outcomes for TBI patients, along with collaborations between academic institutions and pharmaceutical companies, are also fostering innovation in this field. Additionally, the rise of personalized medicine is driving the development of tailored therapeutic approaches that address the unique needs of each patient, enhancing the overall efficacy of TBI treatments. Collectively, these factors are contributing to a dynamic and rapidly evolving market for traumatic brain injury therapeutics.

Select Competitors (Total 86 Featured) -

• Abliva
• Algernon Pharmaceuticals Inc.
• Altasciences
• Astrocyte Pharmaceuticals Inc.
• Beyond Barriers Therapeutics, Inc.
• Cellvation, Inc.
• Ischemix
• Mitochon Pharmaceuticals
• NervGen Pharma Corp.
• Neuren Pharmaceuticals Ltd.
• SanBio Company Limited
• Symbinas Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• ZyVersa Therapeutics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Traumatic Brain Injury Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of TBI Spurs Demand for Effective Therapies
  • Advances in Diagnostic Tools Propel Growth in Market Adoption
  • Technological Innovations in Imaging Techniques Expand Addressable Market Opportunity
  • Emergence of Neuroprotective Agents Strengthens Business Case for Novel Treatments
  • Development of Stem Cell Therapies Generates New Market Opportunities
  • Growing Focus on Personalized Medicine Drives Adoption of Tailored Therapeutic Approaches
  • Enhanced Understanding of TBI Pathophysiology Drives Market Dynamics
  • Growing Awareness of Long-Term Impact of TBI Throws the Spotlight On Need for Comprehensive Care
  • Expanding Field of Regenerative Medicine Sustains Growth in Therapeutic Interventions
  • Integration of Biomarker Discovery and Use in Diagnostics and Treatment Monitoring Generates Demand
  • Non-Pharmacological Interventions, Such as Hyperbaric Oxygen Therapy, Propel Market Growth
  • Increasing Number of Sports-Related TBIs Drives Market Demand
  • Advancements in Transcranial Magnetic Stimulation Generate New Treatment Opportunities
  • Here's the Story: Impact of Military Conflicts on TBI Incidence and Therapeutic Needs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Traumatic Brain Injury Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Traumatic Brain Injury Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Traumatic Brain Injury Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Acetylcholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Acetylcholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Acetylcholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Growth Hormone Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Growth Hormone Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Stem Cells Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Stem Cells Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Stem Cells Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 23: Canada Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: Canada Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: Canada 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• JAPAN
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Japan Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Japan 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• CHINA
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 29: China Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: China Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: China 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• EUROPE
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe Historic Review for Traumatic Brain Injury Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• FRANCE
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: France Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: France 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• GERMANY
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 41: Germany Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Germany Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Germany 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 44: Italy Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Italy Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Italy 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 47: UK Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: UK Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: UK 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of Europe Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of Europe 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Traumatic Brain Injury Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Asia-Pacific Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Asia-Pacific 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 56: Rest of World Recent Past, Current & Future Analysis for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of World Historic Review for Traumatic Brain Injury Therapeutics by Drug Type - Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Rest of World 16-Year Perspective for Traumatic Brain Injury Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Acetylcholinesterase Inhibitors, Erythropoietin Drugs, Growth Hormone Drugs, Stem Cells Drugs and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION